Bone mass response to discontinuation of long-term hormone replacement therapy: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study

Archives of Internal Medicine

Volumn 162, Issue 6, 2002, Pages 665-672

  Greendale, Gail A ^a   Espeland, Mark ^b   Slone, Stacey ^b   Marcus, Robert ^c   Barrett Connor, Elizabeth ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; HIP; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE; TREATMENT OUTCOME;

EID: 0037170596     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.6.665     Document Type: Article

References (29)

1. The menopause
2. Why menopausal women do not want to take hormone replacement therapy
3. Hormone replacement therapy and risk for breast cancer
4. Menopause, estrogen and estrogen-progestin replacement therapy and breast cancer
5. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
6. Estrogen replacement therapy and fractures in older women
7. Hip fracture and the use of estrogens in postmenopausal women: The Framingham study
8. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin interventions (PEPI) trial
9. The pathophysiology and treatment of postmenopausal osteoporosis
10. Bone response to termination of oestrogen treatment
11. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy
12. Magnitude and pattern of skeletal response to long-term continuous and cyclic sequential oestrogen/progestin treatment
13. Effects on bone mass after eight years of hormonal replacement therapy
14. Estrogen: Prevention and treatment of osteoporosis
15. The bone-remodeling transient: Implications for the interpretation of clinical studies of bone mass change
16. Rationale, design, and conduct of the PEPI trial
17. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
18. Effects of hormone replacement therapy on endometdal histology in postmenopausal women
19. Correlates of bone mineral density in the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
20. Leisure, home and occupational physical activity and cardiovascular risk factors in postmenopausal women: The Postmenopausal Estrogens/Progestins Intervention (PEPI) study
21. Lifestyle factors and bone mineral density: The Postmenopausal Estrogen/Progestins Intervention study
22. A databased approach to diet questionnaire design and testing
23. Random effects models for longitudinal data
24. Age at menopause in women participating in the Postmenopausal Estrogen/Progestins interventions (PEPI) trial: An example of bias introduced by selection criteria
25. Timing of postmenopausal estrogen for optimal bone mineral density
26. Longterm prevention of postmenopausal osteoporosis by oestrogen: Evidence for an increased bone mass after delayed onset of oestrogen treatment
27. Five years with continuous combined oestrogen/progestogen therapy: Effects of calcium metabolism, lipoproteins, and bleeding pattern
28. Postmenopausal hormone use following a 3-year randomized clinical trial